
Cristal Therapeutics hires chief business officer from Merck
pharmafile | April 23, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Cristal Therapeutics, Jeroen Tonnaer, MerckÂ
Jeroen Tonnaer has been named as the new chief business officer responsible for Cristal Therapeutics’ business development, partnering and licensing activities.
Tonnaer joins the Dutch firm as a pharma veteran with expertise in drug discovery, development and research strategy, along with partnering and licensing expertise.
As a neuroscientist Jeroen joined Organon in 1982, he held further positions as head DMPK, executive director Toxicology, and executive director global research alliances. Subsequently he was head discovery collaborations Europe for Schering-Plough. Following Schering-Plough’s acquisition by Merck, Jeroen joined Merck in February 2010 to become head of its European External Scientific Affairs team.
“I am delighted to welcome Jeroen to Cristal Therapeutics and look forward to working with him,” remarked chief executive Joost Holthuis. “Jeroen will strengthen our key existing business relationships and focus on finding, executing and fostering new partnering opportunities for Cristal Therapeutics.”
Related Content

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …






